Form 4: Ultragenyx Director Amrit Ray Reports Stock and Option Awards

Director Amrit Ray reports the acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.

Summary

• On May 15, 2025, Director Amrit Ray acquired 5,740 shares of common stock in the form of Restricted Stock Units (RSUs) and options to purchase 10,787 shares of common stock at an exercise price of $34.84.
• The RSUs and options vest fully on the earlier of the company's next Annual Meeting of Stockholders or May 15, 2026.
• Following the transaction, Mr. Ray directly owns 23,365 shares of Ultragenyx Pharmaceutical Inc. common stock and options to purchase 10,787 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard executive compensation practices. The awards suggest confidence, but it's a routine filing.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.
• The vesting schedule incentivizes the director to remain with the company and contribute to its success.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock and option awards align the director's interests with those of shareholders, potentially leading to increased shareholder value.

Key Dates

Keywords

Ultragenyx Pharmaceutical Inc., Director, Amrit Ray, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, RARE